A new consumer-facing company launched Tuesday a preventive healthcare membership that combines a clinical team with biomarker testing, clinical artificial intelligence, wearable data and medical history.
Sonata “connects the dots” across members’ biology and medical history to create personalized care plans—and bridge gaps by offering testing not commonly offered in routine primary care, according to executives.
The membership service is now available to patients in New York, San Francisco and Los Angeles, with plans to expand elsewhere, according to a July 14 press release.
The company was co-founded by Sagan Schultz, M.D., and David Deng. Schultz was the first product manager at Linear and a former McKinsey healthcare consultant. Deng was a first-10 engineer at Ramp and former member of the clinical genomics team at Flatiron Health. The company is backed by Lux Capital, Box Group and Sunflower Capital.
Schultz, who also serves as Sonata’s CEO, told Fierce Healthcare in an emailed statement while people know “more about their own health than ever,” almost “none of it turns into actual care.”
“They're tracking everything, reading the studies, asking ChatGPT to make sense of it all, and still no one is carrying that complexity for them,” Schultz said. “We built Sonata so they don't have to.”
Schultz added board-certified physicians “go deep” into patients’ biology with continual care and AI, which the company built in-house, to aid in discovering patterns.
“The AI connects the dots,” Schultz said. “Every clinical decision belongs to the physician."
Annual membership costs $4,000 with “founding member” pricing at $2,500 annually, according to its website. Membership includes unlimited, continuous care with licensed physicians, in-home blood testing, clinical AI, genome sequencing and more.
"Modern medicine is built on population averages, but no individual is the average,” Deng said in a statement. “Someone with an elevated genetic predisposition to a condition may need a different screening schedule, different monitoring, and different targets.”
Deng said the company’s clinical AI synthesizes members’ “genomics, epigenetics, biomarkers, and health records against clinical guidelines” and current peer-reviewed research to allow physicians to focus on listening to patients building “truly personalized care plans.”